HeartSciences Inc. Income Statement
HSCS|3 years of annual SEC 10-K data (FY2023-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 3 fiscal years. All figures from audited SEC 10-K filings.
HeartSciences Inc. reported $18,600 in revenue and $7M in net loss for FY2025. Revenue has grown at a 13.8% compound annual rate over the past 2 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -5.89 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $18.6K | $5.2K | $14.4K |
| Cost of Revenue | $6.1K | $2.8K | $7.9K |
| Gross Profit | $12.5K | $2.4K | $6.5K |
| SG&A Expense | $3.4M | $3.7M | $1.7M |
| R&D Expense | $2.9M | $2.5M | $3.0M |
| Operating Income | -$6.3M | -$6.1M | -$4.7M |
| Interest Expense | - | $243.2K | $371.6K |
| Net Income | -$6.6M | -$6.4M | -$4.8M |
| EPS (Basic) | -$18.74 | -$80.00 | -$1.45 |
| EPS (Diluted) | -$18.74 | -$80.00 | -$1.45 |
| Shares Outstanding | 676.6K | 101.3K | 3.3M |
| Gross Margin | 67.3% | 45.7% | 45.1% |
| Operating Margin | -33902.0% | -118698.3% | -32765.6% |
| Profit Margin | -35511.9% | -123384.3% | -33592.6% |